ALNA News and Press, Allena Pharmaceuticals Inc. From 09/30/20

Gainers: CTI BioPharma (CTIC) +99%, Genetron Holdings (GTH) +26%, Allena Pharmaceuticals (ALNA) +23%, Neurotrope (NTRP) +20%, Kaleido Biosciences (KLDO) +11%.Losers: Aptorum Group (APM) -41%, Adial Pharmaceuticals (ADIL) -21%, Avalon...

Should These Penny Stocks Be On Your Pre What are penny stocks ? Based on the standard definition, we’re talking about stocks under $5. But obviously, there’s more to it than just price, right? Looking for cheap stocks to buy might seem like an easy task. Just find...

Allena Pharmaceuticals (ALNA) soars 44% in premarket on robust volume, in reaction to $25M convertible debt financing agreement with Pontifax Medison Finance.Under the terms of the agreement, Allena will have access to up to $25M in three tranches, which will mature over a four year...

-- Extends Allena’s Cash Runway into 4Q 2021 -- -- Debt Can be Converted into Equity at a Price of $4.10 Per Share -- NEWTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to d...

Allena Pharmaceuticals ( ALNA -1.3% ) has dosed the first patient in a Phase 1 trial of ALLN-346, for the treatment of hyperuricemia (elevated levels of uric acid in the blood) in patients with gout and advanced chronic kidney disease (CKD). More news on: Allena Pharma...

NEWTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...

NEWTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, ...

Allena Pharmaceuticals (NASDAQ: ALNA ) : Q2 GAAP EPS of -$0.26 beats by $0.02 . More news on: Allena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

-- Expanding URIROX-2 Trial Sites; Interim Analysis on Track for the First Quarter of 2022 –- -- Initiated Phase 1 Clinical Trial of ALLN-346; Initial Data Expected in the Fourth Quarter of 2020 –- -- Raised Gross Proceeds of $22.7M Through Two Public Offerings, Exte...

NEWTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...